Status:
COMPLETED
Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery
Lead Sponsor:
Roswell Park Cancer Institute
Conditions:
Lung Cancer
Eligibility:
All Genders
18-120 years
Phase:
NA
Brief Summary
RATIONALE: Diagnostic procedures using fludeoxyglucose F 18 and a surgical probe may help find lymph node metastases in patients with early-stage non-small cell lung cancer. PURPOSE: This clinical tr...
Detailed Description
OBJECTIVES: Primary * Determine the positive threshold of lymph node radioactivity after fludeoxyglucose F 18, utilizing the gamma probe, in patients with resectable stage I or II non-small cell lun...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of non-small cell lung cancer
- Stage I-II disease
- Resectable disease
- Planning to undergo surgical resection
- No tumors that are not fludeoxyglucose F 18 (FDG)-avid on PET scan
- PATIENT CHARACTERISTICS:
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception
- No previous allergic reaction to fludeoxyglucose F 18
- No contraindication to a pulmonary lobectomy and lymphadenectomy
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
July 16 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 26 2017
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00732563
Start Date
July 16 2008
End Date
July 26 2017
Last Update
October 18 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263-0001